Sara Small, MD, PhD

Sara Small, MD, PhD
​​
This physician is not currently rated. Why?

Why is this doctor not rated?

Close

To ensure the accuracy of our patient satisfaction scores, we require that providers who see patients receive a minimum number of completed patient-submitted surveys before their reviews are listed on their profiles. Star ratings on this site are collected on a rolling basis from the previous 12 months.
Additionally, some of the physicians listed on our site do not see patients directly, and therefore, do not receive evaluation and ratings from patients.

More about patient ratings

Assistant Professor

Specialties

Treatment Focus

Acute Myeloid Leukemia

Research Program

Key Awards

  • American Society of Hematology Research Training Award for Fellows (2023)
  • Hematology/Oncology Fellowship Award (2020)
  • Residency Excellence in Teaching Award (2019)
  • NIH Individual NRSA MD/PhD Fellowship, Granted by the National Institute of Aging (Sept 2013-2015): “Cell-Extrinsic and Cell-Intrinsic Factors in Stem Cell-Dependent Aging”
  • Patel Scholars Award, Granted by the University of Pennsylvania, in recognition of a top impact score among awarded F30/F31 fellowships (2013-2015)
  • Travel Award, 2013 Alliance for Healthy Aging Symposium in Groningen, Netherlands

Clinical Locations

Educational Background

University of Pennsylvania School of Medicine (Medical Scientist Training Program), Philadelphia, PA (2009-2017),

  • M.D., Graduation: May 2017
  • Ph.D., Cellular and Molecular Biology (August 2015)

Columbia University, New York, NY (2003-2007) B.A., Religion

Selected Publications

Small S, Oh T, Platanias LC. Role of biomarkers in the management of acute myeloid leukemia. Int J Mol Sci. 2022: 23(23):14543.

Small S, Tang E, Ragland R, Ruzankina Y, Schoppy D, Glineburg M, Ustelenca Z, Powell D, Simpkins F, Johnson F, and Brown E. Induction of Interleukin-19 through JNK and cGAS-STING modulates DNA-damage-induced cytokine expression. Sci Signal. 2021 Dec. 

Small S, Numan Y, and Platanias LC. 2021. Innate immune mechanisms and immunotherapy in myeloid malignancies. Biomedicines. 2021 Nov;9(11):1631.

Small S, Altman JK, and Platanias LC. Interferon maintenance for prevention of relapse in favorable risk AML? Leuk Lymphoma. 2021 Dec;62(12):2818-2819. 

Small S and Ma S. Frontline treatment for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): targeted therapy versus chemoimmunotherapy. Curr Hematol Malig Rep. 2021 Aug;16(4):325-335. 

Mina A, Small S, and Platanias LC. 2021. Convalescent hyperimmune plasma in patients with hematologic malignancies and severe COVID-19 infections. Leuk Lymphoma. 2021 Jun;62(6):1284-1286.

Small S, Barnea Slonim L, Williams C, and Karmali R. B cell lymphomas of the GI tract. Curr Gastroenterol Rep. 2021 May;23(7):9. 

Small S, Keerthivasan G, Huang Z, Gurbuxani S, and Crispino JD. Overexpression of Survivin Initiates Hematologic Malignancies in Vivo. Leukemia. 2010 Nov;24(11):1920–1926.

Keerthivasan G, Small S, Liu H, Wickrema A, and Crispino JD. Vesicle Trafficking Plays a Novel Role in Erythroblast Enucleation. Blood. 2010 Oct;116(17):3331–3340.

Wen Q, Leung C, Huang Z, Small S, Reddi AL, Licht JD, and Crispino JD. Survivin Is Not Required for the Endomitotic Cell Cycle of Megakaryocytes. Blood. 2009;114(1):153–156.

Baldwin BR, Li L, Tse K-F, Small S, Collector M, Whartenby KA, Sharkis SJ, Racke F, Huso D, and Small D. Transgenic Mice Expressing Tel-FLT3, a Constitutively Activated Form of FLT3, Develop Myeloproliferative Disease. Leukemia. 2007 Apr;21(4):764–771.
 

The following ratings and reviews are based on verified feedback collected from independently administered patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions. Patient identities are withheld to ensure confidentiality and privacy. Learn more about our Patient Experience Ratings.

Ratings Breakdown

Loading ...

Patient comments

Loading ...
​​
Resize Text

Related Articles